US2890152A - Topical anti-inflammatory compositions - Google Patents
Topical anti-inflammatory compositions Download PDFInfo
- Publication number
- US2890152A US2890152A US624961A US62496156A US2890152A US 2890152 A US2890152 A US 2890152A US 624961 A US624961 A US 624961A US 62496156 A US62496156 A US 62496156A US 2890152 A US2890152 A US 2890152A
- Authority
- US
- United States
- Prior art keywords
- percent
- methylsulfate
- diphemanil methylsulfate
- compositions
- diphemanil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 30
- 230000000699 topical effect Effects 0.000 title description 7
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- BREMLQBSKCSNNH-UHFFFAOYSA-M diphemanil methylsulfate Chemical compound COS([O-])(=O)=O.C1C[N+](C)(C)CCC1=C(C=1C=CC=CC=1)C1=CC=CC=C1 BREMLQBSKCSNNH-UHFFFAOYSA-M 0.000 claims description 22
- 229960000591 diphemanil methylsulfate Drugs 0.000 claims description 21
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 229960000890 hydrocortisone Drugs 0.000 claims description 9
- 229960005205 prednisolone Drugs 0.000 claims description 9
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 9
- 150000003431 steroids Chemical class 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 235000019271 petrolatum Nutrition 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 239000004264 Petrolatum Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 229940066842 petrolatum Drugs 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000000812 cholinergic antagonist Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- -1 piperidylidene Chemical class 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 208000005005 intertrigo Diseases 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940126702 topical medication Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 125000000017 cortisol group Chemical group 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000010093 eczematous lesion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 229960002214 methantheline bromide Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229960005439 propantheline bromide Drugs 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
Definitions
- This invention relates to therapeutic compositions and more particularly to compositions which are useful in the treatment of various dermatogical conditions.
- topical preparations comprising a combination of diphemanil methylsulfate (4-diphenylmethylene-1,1-dimethylpiperidinium methyl sulfate) with hydrocortisone or prednisolone 1,4-pregnadiene-l 15,1711, 21-triol-3,20-dione) offer a long-awaited adjunct in the treatment of a variety of skin diseases.
- Our new compositions are useful in treating conditions such as dyshidrotic eczematous lesions caused by drug allergies.
- an ester such as a 2l-acetate or soluble stable ester of phosphoric acid and the like.
- the composition is especially applicable in the treatment of the disease generally known as intertrigo which is aggravated by sweating and friction between opposing skin surfaces. 'Lesions which occur in the armpit due from sensitivity to a deodorant, for example, and the common diaper ras quickly disappear following local application of our therapeutic combination. Furthermore, many dermatological conditions such as lichen planus, those arising from food ordrug allergies, athletes foot, intertrigo, and the like, are accompanied by severe pruritis, or itching, with weeping of the lesion. The new compositions of this invention have-demonstrated remarkable ability in overcoming pruritic and Weeping manifestations. By so removing the desire to scratch and further aggravate the sores, the topical preparations hasten the cure ofthe disease.
- compositions consist essentially of the active ingredients suspended or dissolved in a carrier suitable for topical application such as a hydrocarbon base of the petrolatum type, absorption bases, hydrophilic petrolatum bases, water-soluble bases containing polyethylene glycols and lotions.
- a carrier suitable for topical application such as a hydrocarbon base of the petrolatum type, absorption bases, hydrophilic petrolatum bases, water-soluble bases containing polyethylene glycols and lotions.
- a water-soluble base is preferred so as to permit proper healing of weeping lesions and overcome inteltrigo.
- Diphemanil methylsulfate is particularly adaptable to incorporation into water-soluble bases and water containing bases by virtue iCQ 2 of its stability. It is indeed surprising that of the large number of anticholinergic agents of the quaternary amine type which are in common use in medical therapy, only one, diphemanil methylsulfate, is stable under hydrous conditions.
- the active ingredients of our novel compositions can be incorporated into any suitable ointment or cream base to provide the topical preparations of the present invention.
- suitable bases are given in the specific examples hereinafter set forth. The nature and composition of such bases are well-known and well understood by those skilled in the preparation and employment of topical medications. While each of the active ingredients present in the compositions of the present invention is ordinarily employed in proportions of from about 0.1 percent to 2.5 percent by weight of the final composition, proportions outside this range can also be used, such as 0.1 to 4 percent diphemanil methylsulfate and 0:1 to 4 percent steroid. For achievement of optimum results, it has been determined that the preferred proportions of the active ingredients present in the composition should be one percent of the cortical hormone and two percent of anticholinergic agent.
- compositions of the present invention can be readily prepared by conventional procedures used in the preparation of topical ointments or creams.
- the active ingredients can be incorporated into any suitable ointment of cream base by simply admixing in a suitable agitating device, such as a mixer or blender.
- EXAMPLE 4 Hydrocarbon ointment Parts Prednisolone 10 Diphemanil methylsulfate 25 Petrolatum U.S.P. 965 1000 A slurry of the prednisolone and diphemanil methylsulfate in about 100 parts of petrolatum is milled. The remainder of the petrolatum is then added and the batch is mixed in an ointment mixture until uniform.
- EXAMPLE 5 Absorption formulation Parts Cholesterol 30 Stearyl alcohol 30 White Wax 80 White petrolatum 830 Diphemanil methylsulfate 20 Hydrocortisone Cholesterol is added to a warm melt of the stearyl alcohol, Wax, and petrolatum. The mixture is stirred until the cholesterol completely dissolves. Hydrocortisome is then mixed in by stirring. Diphemanil methylsulfate is added and the mixture is thoroughly stirred and cooled until it congeals.
- This formulation is prepared in the same manner as the hydrophilic preparation of Example 3 except that the petrolatum is omitted.
- a therapeutic composition of matter comprising a steroid of the group consisting of hydrocortisone and prednisolone in combination with diphemanil methylsulfate and a carrier.
- a therapeutic composition of matter comprising from about 0.1 percent to about 4.0 percent of a steroid defined in claim 1, from about 0.1 percent to about 4.0 percent diphemanil methylsulfate, the remainder of the composition comprising a viscous supporting carrier.
- a therapeutic composition of matter comprising from about 0.1 percent to about 2.5 percent of a steroid defined in claim 1, from about 0.1 percent to about 2.5 percent of diphemanil methylsulfate, the remainder of the composition comprising a viscous supporting carrier.
- a therapeutic composition of matter comprising essentially the following:
- Prednisolone Diphemanil methylsulfate in an aqueous glycol vehicle.
- a therapeutic composltion of matter comprising essentially the following:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
United States Patent 2,890,152 TOPICAL AN'II-INFLAMlVIATORY COMPOSITIONS No Drawing. Application November 29, 1956 Serial, No. 624,961
7 Claims. (Cl. 167-65) This invention relates to therapeutic compositions and more particularly to compositions which are useful in the treatment of various dermatogical conditions.
We have found that topical preparations comprising a combination of diphemanil methylsulfate (4-diphenylmethylene-1,1-dimethylpiperidinium methyl sulfate) with hydrocortisone or prednisolone 1,4-pregnadiene-l 15,1711, 21-triol-3,20-dione) offer a long-awaited adjunct in the treatment of a variety of skin diseases. Our new compositions are useful in treating conditions such as dyshidrotic eczematous lesions caused by drug allergies. In place of the free sterol there may be used, in some cases, an ester such as a 2l-acetate or soluble stable ester of phosphoric acid and the like. The composition is especially applicable in the treatment of the disease generally known as intertrigo which is aggravated by sweating and friction between opposing skin surfaces. 'Lesions which occur in the armpit due from sensitivity to a deodorant, for example, and the common diaper ras quickly disappear following local application of our therapeutic combination. Furthermore, many dermatological conditions such as lichen planus, those arising from food ordrug allergies, athletes foot, intertrigo, and the like, are accompanied by severe pruritis, or itching, with weeping of the lesion. The new compositions of this invention have-demonstrated remarkable ability in overcoming pruritic and Weeping manifestations. By so removing the desire to scratch and further aggravate the sores, the topical preparations hasten the cure ofthe disease.
The new therapeutic combinations, described in more detail below, are thus highly effective agents in combatting a host of skin diseases. It is indeed surprising that the particular combination of diphemanil methylsulfate with hy rocortisone orprednisolone enables control of conditions whichare resistant to the action of either active ingredient when used alone.-
' The mode of action ofthecomposition is unknown although absorption of the medicament at the site apparently occurs whereby the development of tissue reaction is counteracted. No toxic reactions arising from the composition have been observed.
There appears to be a potentiation of each of the active ingredients upon each other. Although large doses of hydrocortisone have been used internally or topically to combat certain skin diseases, the presence of diphemanil methylsulfate permits the use of a smaller dose of the corticoid.
Our new compositions consist essentially of the active ingredients suspended or dissolved in a carrier suitable for topical application such as a hydrocarbon base of the petrolatum type, absorption bases, hydrophilic petrolatum bases, water-soluble bases containing polyethylene glycols and lotions. In certain instances a water-soluble base is preferred so as to permit proper healing of weeping lesions and overcome inteltrigo. Diphemanil methylsulfate is particularly adaptable to incorporation into water-soluble bases and water containing bases by virtue iCQ 2 of its stability. It is indeed surprising that of the large number of anticholinergic agents of the quaternary amine type which are in common use in medical therapy, only one, diphemanil methylsulfate, is stable under hydrous conditions. This distinct property is not easily explained but may be due to the chemical structure of diphemanil methylsulfate. The substance is a piperidylidene derivative while for the most part all other anticholinergics are structurally related to atropine and/or contain a dialkaminoalkyl grouping. Laboratory testing of other anticholinergic agents such as methantheline bromide, methscopolamine bromide, propantheline bromide, tricyclarnol methylsulfate, and the like, have demonstrated their incompatibility with hydrous media. Thus our compositions are inherently unique in their content.
The active ingredients of our novel compositions can be incorporated into any suitable ointment or cream base to provide the topical preparations of the present invention. Representative examples of suitable bases are given in the specific examples hereinafter set forth. The nature and composition of such bases are well-known and well understood by those skilled in the preparation and employment of topical medications. While each of the active ingredients present in the compositions of the present invention is ordinarily employed in proportions of from about 0.1 percent to 2.5 percent by weight of the final composition, proportions outside this range can also be used, such as 0.1 to 4 percent diphemanil methylsulfate and 0:1 to 4 percent steroid. For achievement of optimum results, it has been determined that the preferred proportions of the active ingredients present in the composition should be one percent of the cortical hormone and two percent of anticholinergic agent.
The compositions of the present invention can be readily prepared by conventional procedures used in the preparation of topical ointments or creams. For example, the active ingredients can be incorporated into any suitable ointment of cream base by simply admixing in a suitable agitating device, such as a mixer or blender.
The novel topical medications of the persent invention are illustrated by the following examples which are presented for illustrative purposes only.
EXAMPLE 1 Water soluble cream Parts Prednisolone 5.0 Diphemanil methylsulfate 20.0 Zinc stearate 60.0 Polyethylene Glycol i500 405.0 Polyethylene Glycol 6000 120.0 Propylene glycol 350.0 Distilled H O 40.0
EXAMPLE 2 Water soluble ointment Parts Diphemanil methylsulfate 20.0 Hydrocortisone 10.0 Zinc stearate 200.0
CarbOWaX 1500 549.0 Distilled Water 221.0
EXAMPLE 3 Water-removable or hydrophilic preparation Hydrocortisone Parts Hydrocortisone 10.00 Diphemanil methylsulfate 40.00 Methyl Paraben 0.25 Propyl Paraben 0.15 Steryl alcohol 245.00 White petrolatum 245.00 Propylene glycol 120.00 Polyoxyethylene lauryl alcohol 50.00 Distilled Water 290.00 1000.00
EXAMPLE 4 Hydrocarbon ointment Parts Prednisolone 10 Diphemanil methylsulfate 25 Petrolatum U.S.P. 965 1000 A slurry of the prednisolone and diphemanil methylsulfate in about 100 parts of petrolatum is milled. The remainder of the petrolatum is then added and the batch is mixed in an ointment mixture until uniform.
EXAMPLE 5 Absorption formulation Parts Cholesterol 30 Stearyl alcohol 30 White Wax 80 White petrolatum 830 Diphemanil methylsulfate 20 Hydrocortisone Cholesterol is added to a warm melt of the stearyl alcohol, Wax, and petrolatum. The mixture is stirred until the cholesterol completely dissolves. Hydrocortisome is then mixed in by stirring. Diphemanil methylsulfate is added and the mixture is thoroughly stirred and cooled until it congeals.
4 EXAMPLE 6 Lotion preparation Parts Diphemanil methylsulfate 30 Prednisolone 5 Methyl Paraben 0.25 Propyl Paraben 0.15 Stearyl alcohol 245 Propylene glycol 50 Polyoxyethylene lauryl alcohol 10 Distilled water, q.s. to a total of 1000 parts.
This formulation is prepared in the same manner as the hydrophilic preparation of Example 3 except that the petrolatum is omitted.
Having disclosed our invention, what we claim to be new and wish to secure by Letters Patent is:
1. A therapeutic composition of matter comprising a steroid of the group consisting of hydrocortisone and prednisolone in combination with diphemanil methylsulfate and a carrier.
2. A therapeutic composition of matter comprising from about 0.1 percent to about 4.0 percent of a steroid defined in claim 1, from about 0.1 percent to about 4.0 percent diphemanil methylsulfate, the remainder of the composition comprising a viscous supporting carrier.
3. A therapeutic composition of matter comprising from about 0.1 percent to about 2.5 percent of a steroid defined in claim 1, from about 0.1 percent to about 2.5 percent of diphemanil methylsulfate, the remainder of the composition comprising a viscous supporting carrier.
4. A therapeutic composition of matter according to claim 2 in which the steroid is hydrocortisone.
5. A therapeutic composition of matter according to claim 2 in which the steroid is prednisolone.
6. A therapeutic composition of matter comprising essentially the following:
Percent by weight 0.1 to 2.5 0.1 to 2.5
Prednisolone Diphemanil methylsulfate in an aqueous glycol vehicle.
7. A therapeutic composltion of matter comprising essentially the following:
Percent by weight Hydrocortisone 0.1 to 2.5 Diphemanil methylsulfate 0.1 to 2.5
in an aqueous glycol vehicle.
References Cited in the file of this patent
Claims (1)
1. A THERAPEUTIC COMPOSITION OF MATTER COMPRISING A STEROID OXF THE GROUP CONSISTING OF HYDROCORTISONE AND PREDNISOLONE IN COMBINATION WITH DIPHEMANIL METHYLSULFATE AND A CARRIER.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US624961A US2890152A (en) | 1956-11-29 | 1956-11-29 | Topical anti-inflammatory compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US624961A US2890152A (en) | 1956-11-29 | 1956-11-29 | Topical anti-inflammatory compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2890152A true US2890152A (en) | 1959-06-09 |
Family
ID=24504037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US624961A Expired - Lifetime US2890152A (en) | 1956-11-29 | 1956-11-29 | Topical anti-inflammatory compositions |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2890152A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174963A (en) * | 1960-12-01 | 1965-03-23 | Union Carbide Corp | Chloroquine adenylic nucleotides |
| US3186991A (en) * | 1962-03-22 | 1965-06-01 | Boehringer Sohn Ingelheim | 5,6,7,8-tetrahydro-pyrido-[4,3-d]-pyrimidines |
| US3248395A (en) * | 1962-03-22 | 1966-04-26 | Boehringer Sohn Ingelheim | 4-amino-5, 6, 7, 8-tetrahydro-pyrido-[4, 3-d]-pyrimidine substitution products |
| US3306901A (en) * | 1962-03-22 | 1967-02-28 | Boehringer Sohn Ingelheim | 4-hydroxy-5,6,7,8-tetrahydro-pyrido-[4,3-d]-pyrimidine substitution products |
| US4049792A (en) * | 1973-06-26 | 1977-09-20 | The Procter & Gamble Company | Antiperspirant stick |
| US4353896A (en) * | 1981-06-08 | 1982-10-12 | Levy Michael A | Penetrating topical medicament |
| US4664910A (en) * | 1981-01-26 | 1987-05-12 | Lever Brothers Company | Cosmetic composition |
| US4775529A (en) * | 1987-05-21 | 1988-10-04 | Schering Corporation | Steroid lotion |
| US5635497A (en) * | 1982-06-23 | 1997-06-03 | Yamanouchi Europe B.V. | Topical application compositions |
-
1956
- 1956-11-29 US US624961A patent/US2890152A/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| None * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174963A (en) * | 1960-12-01 | 1965-03-23 | Union Carbide Corp | Chloroquine adenylic nucleotides |
| US3186991A (en) * | 1962-03-22 | 1965-06-01 | Boehringer Sohn Ingelheim | 5,6,7,8-tetrahydro-pyrido-[4,3-d]-pyrimidines |
| US3248395A (en) * | 1962-03-22 | 1966-04-26 | Boehringer Sohn Ingelheim | 4-amino-5, 6, 7, 8-tetrahydro-pyrido-[4, 3-d]-pyrimidine substitution products |
| US3306901A (en) * | 1962-03-22 | 1967-02-28 | Boehringer Sohn Ingelheim | 4-hydroxy-5,6,7,8-tetrahydro-pyrido-[4,3-d]-pyrimidine substitution products |
| US4049792A (en) * | 1973-06-26 | 1977-09-20 | The Procter & Gamble Company | Antiperspirant stick |
| US4664910A (en) * | 1981-01-26 | 1987-05-12 | Lever Brothers Company | Cosmetic composition |
| US4353896A (en) * | 1981-06-08 | 1982-10-12 | Levy Michael A | Penetrating topical medicament |
| US5635497A (en) * | 1982-06-23 | 1997-06-03 | Yamanouchi Europe B.V. | Topical application compositions |
| US4775529A (en) * | 1987-05-21 | 1988-10-04 | Schering Corporation | Steroid lotion |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4185100A (en) | Topical anti-inflammatory drug therapy | |
| EP0189738A1 (en) | Topical compositions for preventing or treating dry skin | |
| FI95350B (en) | Procedure for the preparation of topically useful drug lotions for the management of inflammation | |
| US4282216A (en) | Topical anti-inflammatory drug therapy | |
| JPS6135166B2 (en) | ||
| US4012508A (en) | Topical composition and method | |
| US4879274A (en) | External medication for skin | |
| US2890152A (en) | Topical anti-inflammatory compositions | |
| WO2014138501A2 (en) | Compositions and methods for the treatment of skin diseases | |
| JPH03204815A (en) | Therapeutic composition for treating dermatological disease carried by mast cell | |
| CN106344589B (en) | A kind of Calcipotriol betamethasone composition of improved stability | |
| EP1957080A2 (en) | Topical glucocorticosteroid formulations | |
| JPH0473413B2 (en) | ||
| US3352753A (en) | Pharmaceutical compositions of corticosteroids in gelled alcohol | |
| GB2068227A (en) | Topical ointment | |
| JPH0353286B2 (en) | ||
| CA2581364A1 (en) | Treatment of dermatitis with dehydroepiandrosterone-glucocorticoid combinations | |
| Cream | Summary of product characteristics | |
| RU2223765C1 (en) | Anti-inflammatory and anti-allergic composition | |
| GB2148116A (en) | Topical steroid preparations | |
| JP2024048695A (en) | External composition for treatment of dermatitis | |
| US3173836A (en) | Method and compositions for the treatment of cutaneous herpetic infections | |
| JPH06256153A (en) | Antiphlogistic cosmetic | |
| PT1341515E (en) | Water-free skin care formulations comprising micronized urea and method of manufacturing the same | |
| IL42365A (en) | Anti-inflammatory topical composition containing 2-(4-pyridyl-6,16alpha-dimethyl-11beta,17alpha,21-trihydroxypregna-4,6-dieno(3,2-c)-pyrazol-20-one |